Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05432466 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome

Study acronym: DiSCOVER
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv9
  2. Primary completion date: Oct 30, 2025 to Mar 1, 2029
    • Study completion date: Nov 30, 2025 to Apr 1, 2029
    • Eligibility criteria shortened, about 5 words
    v8
  3. Re-verified, no change to tracked fieldsv7
  4. Start date: Jun 28, 2022 to Nov 7, 2022v6
  5. Trial status: Enrolling by Invitation to Recruiting
    • Site details revised
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Recruiting to Enrolling by Invitation
    • Start date changed from estimate of Aug 2022 to Jun 28, 2022
    • Site details revised
    v4
  2. Start date: Jun 30, 2022 to Aug 2022v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, Phase 3, randomized, double-blind, placebo-controlled efficacy study to evaluate celiprolol in patients genetically confirmed as COL3A1-positive vEDS using a decentralized clinical trial design.
Trial Details
NCT Number NCT05432466
Lead Sponsor Acer Therapeutics Inc.
Conditions
(from sponsor)		 Vascular Ehlers-Danlos Syndrome
Related terms Ehlers-Danlos Syndrome, Type IV
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov